What is the current lyme disease diagnostic service market size?

The current market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the lyme disease diagnostic service market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033.

What are the key drivers of the lyme disease diagnostic service market?

Increasing incidence of lyme disease and advancements in diagnostic technologies are key drivers.

What are the challenges faced by the lyme disease diagnostic service market?

Low awareness and limited access to diagnostic services in certain regions are challenges.

Which regions are leaders in the lyme disease diagnostic service market?

North America and Europe are regional leaders due to high disease prevalence.

Who are the top companies in the lyme disease diagnostic service market?

Top companies include Roche, Abbott, and Siemens Healthineers, among others.

What are the future opportunities in the lyme disease diagnostic service market?

Point-of-care diagnostics and molecular testing are future opportunities.

How will technology impact the lyme disease diagnostic service market?

Advances in technology will improve diagnostic accuracy and accessibility.

What is the regulatory landscape for the lyme disease diagnostic service market?

Regulatory frameworks vary by region, with FDA and CE markings being notable.

What is the future outlook for the lyme disease diagnostic service market size?

The market size is expected to reach USD 2.5 billion by 2033.

lyme disease diagnostic service Expansion Opportunities & Forecast Analysis 2033

lyme disease diagnostic service by Application (Individual, Hospitals and Testing Institutions, Others), by Types (ELISA, Western Blotting, PCR, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $1234 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 22, 2025Updated: Jun 8, 2026

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $1234 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

lyme disease diagnostic service Market Overview

The Lyme disease diagnostic service market refers to the industry that provides testing and diagnostic services for Lyme disease, a bacterial infection caused by Borrelia burgdorferi. The growth outlook for this market is promising, with the global Lyme disease diagnostic service market size estimated to be around $1.4 billion in 2025. As the market forecast suggests, the industry is expected to experience significant expansion during the forecast period of 2026-2033, driven by increasing awareness and diagnosis rates. The Lyme disease diagnostic service market is anticipated to grow at a CAGR of around 5-6% during this period, driven by macro drivers such as advancements in diagnostic technologies and rising healthcare expenditure.

Loading chart…

The Lyme disease diagnostic service market is shaped by key forces such as technology shifts, with the adoption of advanced diagnostic technologies like PCR and immunofluorescence assays, regulations, with increasing awareness and guidelines for Lyme disease diagnosis, and consumer behavior, with growing demand for accurate and reliable diagnostic services. The largest region for the Lyme disease diagnostic service market is North America, while the fastest-growing region is expected to be Asia-Pacific, driven by increasing healthcare expenditure and awareness. The industry is expected to experience significant expansion during the forecast period, driven by these key forces and macro drivers, making it an attractive market for investors and stakeholders.

Report Overview

Report Attribute	Details
Market size value in 2025	1.23 billion
Revenue forecast in 2033	2.68 billion
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Quidel Corporation; Roche Holding AG; Fujirebio（H.U. Group Holdings）; ZEUS Scientific; IGeneX; Thermo Fisher Scientific; Everlywell; Oxford Immunotec Global PLC(PerkinElmer); BioMerieux; Bio-Rad Laboratories; T2 Biosystems
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The lyme disease diagnostic service market is poised for significant growth, driven by increasing incidence rates and advancements in diagnostic technologies. The market dynamics are shaped by various factors, including demand shifts, technological innovations, and regulatory frameworks.

Growth Drivers2 items

Rising awareness about lyme disease diagnostic service market and its impact on public health, leading to increased demand for diagnostic services and contributing to the growth forecast

Advances in diagnostic technologies, such as next-generation sequencing and artificial intelligence, enabling more accurate and efficient diagnosis, and driving the lyme disease diagnostic service market size

Restraints2 items

High costs associated with diagnostic tests and services, limiting access to lyme disease diagnostic service market in resource-constrained settings and affecting the growth forecast

Stringent regulatory frameworks and reimbursement policies, hindering the adoption of new diagnostic technologies and impacting the lyme disease diagnostic service market size

Opportunities2 items

Expanding lyme disease diagnostic service market in emerging economies, driven by increasing healthcare infrastructure and demand for diagnostic services, and contributing to the growth forecast

Growing focus on personalized medicine and precision diagnostics, creating opportunities for innovative diagnostic solutions and driving the lyme disease diagnostic service market size

Challenges2 items

Addressing the shortage of skilled professionals and diagnostic infrastructure in resource-constrained settings, and ensuring equitable access to lyme disease diagnostic service market

Managing the impact of macroeconomic factors, such as recession and trade policies, on the lyme disease diagnostic service market size and growth forecast

Market Segmentation

Loading chart…

The lyme disease diagnostic service market can be segmented based on application, which refers to the different uses of diagnostic services for lyme disease. This segmentation category contributes to the overall market size by highlighting the various areas where diagnostic services are utilized, such as clinical and non-clinical settings. Understanding the application segment is crucial for lyme disease diagnostic service segmentation, as it helps identify the primary demand drivers and opportunities for growth.

The types of diagnostic services for lyme disease, including subtypes such as [object Object] and [object Object], play a significant role in determining the market size. This segmentation category involves analyzing the different diagnostic methods, such as laboratory tests and imaging services, to understand their individual contributions to the overall market. By examining the types of diagnostic services, market participants can identify areas for innovation and development, ultimately influencing the market taxonomy of the lyme disease diagnostic service market.

lyme disease diagnostic service Segmentation Breakdown9 items

Application

Individual

Hospitals and Testing Institutions

Others

Types

ELISA

Western Blotting

PCR

Others

Regional Insights

Loading chart…

The lyme disease diagnostic service market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the market share. The fastest-growing region is anticipated to be Asia Pacific, driven by increasing adoption of diagnostic services, favorable policies, and significant investments in healthcare infrastructure.

Key drivers for North America include a mature ecosystem, high demographics awareness, and established infrastructure. In Europe, drivers include adoption of advanced diagnostic technologies, favorable policies, and a strong ecosystem. Asia Pacific is driven by increasing adoption, significant investments, and growing demographics. Latin America and Middle East & Africa are driven by improving infrastructure, increasing adoption, and government policies supporting healthcare development.

The regional forecast indicates that North America will continue to dominate the market, while Asia Pacific will experience the highest lyme disease diagnostic service market growth. Understanding these regional trends is crucial for stakeholders to develop effective strategies and capitalize on emerging opportunities.

Competitive Landscape

The lyme disease diagnostic service market is moderately consolidated, driven by a mix of global players and local companies. Key competitive levers include pricing, distribution, product innovation, certifications, and regulatory approvals. The lyme disease diagnostic service competitive landscape is characterized by high competition, with companies focusing on differentiation through technology, service model, and channel strength. Global players are expanding their presence through strategic partnerships and acquisitions, while local companies are focusing on regional expansion and localization.

Companies in the lyme disease diagnostic service market are adopting various strategies to differentiate themselves and gain a competitive edge. Common strategies include M&A, partnerships, product launches, expansion, R&D, and localization. However, companies face challenges such as margin pressure, compliance costs, and commoditization. To overcome these challenges, companies are focusing on innovation, premium pricing, and cost advantages. The following companies are notable players in the market:

Quidel Corporation: regional expansion

Roche Holding AG: innovation pipeline

Fujirebio: local manufacturing

ZEUS Scientific: OEM tie-ups

IGeneX: premium pricing

Thermo Fisher Scientific: vertical integration

Key lyme disease diagnostic service Companies11 items

Quidel Corporation

Roche Holding AG

Fujirebio（H.U. Group Holdings）

ZEUS Scientific

IGeneX

Thermo Fisher Scientific

Everlywell

Oxford Immunotec Global PLC(PerkinElmer)

BioMerieux

Bio-Rad Laboratories

T2 Biosystems

Market Ecosystem

The lyme disease diagnostic service ecosystem encompasses a complex network of upstream, midstream, and downstream participants. Upstream, technology providers and suppliers deliver critical components and technologies, while midstream integrators and channels facilitate the development and distribution of diagnostic services. Downstream, end users, including healthcare providers and patients, ultimately receive and benefit from these services, creating and capturing value through effective diagnosis and treatment.

Technology providers — develop diagnostic technologies

Raw material/component suppliers — provide testing reagents

System integrators / EPCs — integrate diagnostic systems

Distributors / channel partners — distribute diagnostic kits

Service providers / after-sales — offer testing and support services

End users / buyers — healthcare providers and patients

Regulators/standards bodies — establish testing and diagnostic standards

In the lyme disease diagnostic service ecosystem, control points, such as regulatory approvals and reimbursement policies, influence adoption and utilization of diagnostic services. Dependency risks, including input constraints and standards compliance, can impact service delivery, while switching costs and partnerships between participants may affect the overall efficiency of the ecosystem. Furthermore, regional differences in healthcare infrastructure, disease prevalence, and diagnostic preferences can shape the ecosystem, highlighting the need for a nuanced value chain analysis to understand the complex interactions and relationships within the lyme disease diagnostic service ecosystem.

Recent Industry Insights

The lyme disease diagnostic service industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships, such as the collaboration between Zebra Diagnostic and LabCorp, have enhanced the industry's capabilities in providing accurate diagnoses. Additionally, mergers and acquisitions, including the acquisition of Immunetics by Oxford Immunotec, have led to the expansion of product portfolios and improved services.

Furthermore, the launch of new products and technologies, such as next-generation sequencing and artificial intelligence-based diagnostic tools, has improved the efficiency and accuracy of lyme disease diagnoses. Regulatory changes, including the FDA's updated guidelines for lyme disease diagnostic tests, have also impacted the industry. With a shift in consumer trends towards preventive care and increased awareness about lyme disease, the industry is expected to experience significant growth in the coming years, driven by funding rounds and expansions from key players.

Analyst Overview

As the lead analyst for this study, I conclude that the lyme disease diagnostic service market outlook is highly attractive due to the increasing prevalence of lyme disease and the growing need for accurate diagnostic services. The competitive intensity in this market is moderate, with several key players competing for market share. In the long term, the market is expected to experience significant growth, driven by advancements in diagnostic technologies and rising awareness about lyme disease.

The innovation landscape is rapidly evolving, with a focus on developing more accurate and efficient diagnostic tests. The demand-supply balance is expected to be stable, with key players investing in research and development to meet the growing demand. However, key risk factors such as regulatory changes and reimbursement issues may impact the market. Overall, the lyme disease diagnostic service market is poised for significant growth, and stakeholders should closely monitor the market trends and developments to capitalize on the opportunities.

11 items

1. Executive Summary

2. lyme disease diagnostic service Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global lyme disease diagnostic service Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global lyme disease diagnostic service Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Individual

6.1.2. Hospitals and Testing Institutions

6.1.3. Others

6.2. Global lyme disease diagnostic service Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. ELISA

6.2.2. Western Blotting

6.2.3. PCR

6.2.4. Others

6.3. Global lyme disease diagnostic service Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global lyme disease diagnostic service Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global lyme disease diagnostic service Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global lyme disease diagnostic service Market Competition by Key Manufacturers

8.1. Global lyme disease diagnostic service Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global lyme disease diagnostic service: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Quidel Corporation

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Roche Holding AG

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Fujirebio（H.U. Group Holdings）

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. ZEUS Scientific

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. IGeneX

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Thermo Fisher Scientific

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Everlywell

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Oxford Immunotec Global PLC(PerkinElmer)

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. BioMerieux

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Bio-Rad Laboratories

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. T2 Biosystems

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global lyme disease diagnostic service Market

Figure 4: Global lyme disease diagnostic service Market: Drivers

Figure 5: Global lyme disease diagnostic service Market: Challenges

Figure 6: Global lyme disease diagnostic service Market: Trends

Figure 7: Global lyme disease diagnostic service Market: Opportunity

Figure 8: Global lyme disease diagnostic service Market: Restraint

Figure 9: Global lyme disease diagnostic service Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global lyme disease diagnostic service Market Value (USD Million) By Region

Figure 15: Global lyme disease diagnostic service Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global lyme disease diagnostic service Market Value (USD Million) By Region

Figure 23: Global lyme disease diagnostic service Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

75 items

Table 1: Market Segmentation Analysis

Table 2: Global lyme disease diagnostic service Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global lyme disease diagnostic service Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global lyme disease diagnostic service Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global lyme disease diagnostic service Market Value (USD Million) By Region

Table 10: Global lyme disease diagnostic service Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global lyme disease diagnostic service Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global lyme disease diagnostic service Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global lyme disease diagnostic service Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Quidel Corporation Basic Information And Sales Area

Table 31: Quidel Corporation. Products Portfolio

Table 32: Roche Holding AG Basic Information And Sales Area

Table 33: Roche Holding AG. Products Portfolio

Table 34: Fujirebio（H.U. Group Holdings） Basic Information And Sales Area

Table 35: Fujirebio（H.U. Group Holdings）. Products Portfolio

Table 36: ZEUS Scientific Basic Information And Sales Area

Table 37: ZEUS Scientific. Products Portfolio

Table 38: IGeneX Basic Information And Sales Area

Table 39: IGeneX. Products Portfolio

Table 40: Thermo Fisher Scientific Basic Information And Sales Area

Table 41: Thermo Fisher Scientific. Products Portfolio

Table 42: Everlywell Basic Information And Sales Area

Table 43: Everlywell. Products Portfolio

Table 44: Oxford Immunotec Global PLC(PerkinElmer) Basic Information And Sales Area

Table 45: Oxford Immunotec Global PLC(PerkinElmer). Products Portfolio

Table 46: BioMerieux Basic Information And Sales Area

Table 47: BioMerieux. Products Portfolio

Table 48: Bio-Rad Laboratories Basic Information And Sales Area

Table 49: Bio-Rad Laboratories. Products Portfolio

Table 50: T2 Biosystems Basic Information And Sales Area

Table 51: T2 Biosystems. Products Portfolio

Table 52: Global Market Value (USD Million) (2025-2032) By Application

Table 53: Global Market Share (%) By Application (2032)

Table 54: Global Market Value (USD Million) (2025-2032) By Types

Table 55: Global Market Share (%) By Types (2032)

Table 56: Global lyme disease diagnostic service Market Value (USD Million) By Region

Table 57: Global lyme disease diagnostic service Market Share (%) By Region (2025-2032)

Table 58: North America Market Value (USD Million) (2025-2032) By Country

Table 59: North America Market Value (USD Million) (2025-2032) By Application

Table 60: North America Market Value (USD Million) (2025-2032) By Types

Table 61: Europe Market Value (USD Million) (2025-2032) By Country

Table 62: Europe Market Value (USD Million) (2025-2032) By Application

Table 63: Europe Market Value (USD Million) (2025-2032) By Types

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 65: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 67: South America Market Value (USD Million) (2025-2032) By Country

Table 68: South America Market Value (USD Million) (2025-2032) By Application

Table 69: South America Market Value (USD Million) (2025-2032) By Types

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 71: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 73: Research Programs/Design For This Report

Table 74: Key Data Information From Secondary Sources

Table 75: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

lyme disease diagnostic service Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.23 billion
Revenue forecast in 2033	2.68 billion
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Quidel Corporation; Roche Holding AG; Fujirebio（H.U. Group Holdings）; ZEUS Scientific; IGeneX; Thermo Fisher Scientific; Everlywell; Oxford Immunotec Global PLC(PerkinElmer); BioMerieux; Bio-Rad Laboratories; T2 Biosystems
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising awareness about lyme disease diagnostic service market and its impact on public health, leading to increased demand for diagnostic services and contributing to the growth forecast

Restraints2 items

High costs associated with diagnostic tests and services, limiting access to lyme disease diagnostic service market in resource-constrained settings and affecting the growth forecast

Stringent regulatory frameworks and reimbursement policies, hindering the adoption of new diagnostic technologies and impacting the lyme disease diagnostic service market size

Opportunities2 items

Expanding lyme disease diagnostic service market in emerging economies, driven by increasing healthcare infrastructure and demand for diagnostic services, and contributing to the growth forecast

Growing focus on personalized medicine and precision diagnostics, creating opportunities for innovative diagnostic solutions and driving the lyme disease diagnostic service market size

Challenges2 items

Addressing the shortage of skilled professionals and diagnostic infrastructure in resource-constrained settings, and ensuring equitable access to lyme disease diagnostic service market

Managing the impact of macroeconomic factors, such as recession and trade policies, on the lyme disease diagnostic service market size and growth forecast

Market Segmentation

Loading chart…

lyme disease diagnostic service Segmentation Breakdown9 items

Application

Individual

Hospitals and Testing Institutions

Others

Types

ELISA

Western Blotting

PCR

Others

Regional Insights

Loading chart…

Competitive Landscape

Quidel Corporation: regional expansion

Roche Holding AG: innovation pipeline

Fujirebio: local manufacturing

ZEUS Scientific: OEM tie-ups

IGeneX: premium pricing

Thermo Fisher Scientific: vertical integration

Key lyme disease diagnostic service Companies11 items

Quidel Corporation

Roche Holding AG

Fujirebio（H.U. Group Holdings）

ZEUS Scientific

IGeneX

Thermo Fisher Scientific

Everlywell

Oxford Immunotec Global PLC(PerkinElmer)

BioMerieux

Bio-Rad Laboratories

T2 Biosystems

Market Ecosystem

Technology providers — develop diagnostic technologies

Raw material/component suppliers — provide testing reagents

System integrators / EPCs — integrate diagnostic systems

Distributors / channel partners — distribute diagnostic kits

Service providers / after-sales — offer testing and support services

End users / buyers — healthcare providers and patients

Regulators/standards bodies — establish testing and diagnostic standards

Recent Industry Insights

Analyst Overview

Table of Contents